Conditions: Multiple Myeloma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 14
Healthy volunteers: no

Brief summary:
One of the complications that can occur after a stem cell transplant is called graft versus host disease (GVHD). Another complication is that multiple myeloma may come back (relapse). In this study, a drug called lenalidomide will be started 1-2 months after a transplant, or possibly later depending on recovery of your side effects. Lenalidomide and sirolimus have been shown to work together against multiple myeloma. Therefore, lenalidomide will be combined with sirolimus with the hope that this will help prolong the amount of time the disease is in remission. Researchers hope these steps will help prolong the amount of time the multiple myeloma is in remission and will decrease the chance of GvHD.

Detailed description:

Arms:
arm 1: Use sirolimus and tacrolimus as GvHD prophylaxis with sirolimus and lenalidomide as post-transplant maintenance

Interventions: intervention 1: Sirolimus intervention 2: Tacrolimus intervention 3: Lenalidomide
Intervention descriptions: intervention 1: Start on Day -3 and continue for 1 year intervention 2: Start on Day -3 and begin tapering on Day +100 until Day +180. intervention 3: Start between Day +30 and +120 and continue for 1 year.

Protocol document: